Soluble microneedle patch for delivering ganciclovir as well as preparation method and application of soluble microneedle patch

Through the soluble microneedle patch of the torch-type needle body, two-step centrifugal drying and hyaluronic acid material, the penetration and solubility of ganciclovir in the skin were solved, and the efficiency of ganciclovir was achieved Delivery and precise therapeutic effects.

CN118986843APending Publication Date: 2024-11-22SHIHEZI UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411145311.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The water solubility of ganciclovir in the body leads to low transmembrane ability, poor penetration of the plasma membrane of lipid-soluble cells, and traditional soluble microneedles cannot completely dissolve in the skin, resulting in low drug delivery efficiency and waste.

Method used

Using a soluble microneedle patch of the torch-type needle body, the drug is enriched at the needle tip through two-step centrifugal drying method, combining hyaluronic acid as the matrix material and backing layer to improve the load and release efficiency of the drug, and through The shape of the torch increases skin penetration.

Benefits of technology

The rapid release and precise delivery of ganciclovir are achieved, the stability of the drug and transdermal absorption efficiency are improved, the toxic side effects are reduced, and the therapeutic effect on Kaposi's sarcoma is significantly improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986843A_ABST
    Figure CN118986843A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedical materials, in particular to a soluble microneedle patch for delivering ganciclovir as well as a preparation method and application of the soluble microneedle patch. The soluble microneedle patch comprises needle bodies and a backing layer, wherein the needle bodies are arranged on the backing layer in an array; the needle body comprises a matrix material and GCVat-ZIF-8, the single needle body is in a flame torch shape, the height of the flame torch is 512 microns, and the height of the pyramid base is 288 microns. The ganciclovir soluble microneedle prepared by the invention has good mechanical strength and can be punctured into the skin, the needle tip can be rapidly dissolved subcutaneously and release the nano-material, and then the nano-material is decomposed to release the ganciclovir drug due to environmental factors, so that transdermal delivery is realized, the problem that ganciclovir is not easy to take in is solved, the HA is used as a matrix material, and the ganciclovir soluble microneedle has a good application prospect. Not only is the quick dissolving effect realized, but also the intake of ganciclovir is assisted to a certain extent, so that the action effect is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedical materials, and in particular to a soluble microneedle patch for delivering ganciclovir, and a preparation method and application thereof. Background Art

[0002] Kaposi's sarcoma associated herpesvirus (KSHV) is an important human tumor virus, which is closely related to the occurrence of malignant diseases such as Kaposi's sarcoma (Kaposi's sarcoma KS), primary effusion lymphoma (Primary effusion lymphoma, PEL) and multicentric Castleman disease (Multicentric Castleman Disease, MCD). Among them, Kaposi's sarcoma is a common tumor and cause of death in AIDS patients. Clinically, it often manifests as malignant invasion of endothelial cells such as multiple spots or plaques on the skin.

[0003] Ganciclovir (GCV) is a highly effective, low-toxic, highly selective broad-spectrum antiviral chemotherapy agent with strong inhibitory activity against six types of herpes virus infections in humans. Ganciclovir can inhibit the replication of herpes viruses in vivo, including herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus. In terms of mode of action, after ganciclovir enters the host cell, it is mainly phosphorylated to ganciclovir triphosphate by one or more cellular kinases induced by sensitive viruses. Its concentration in virus-infected cells can be 100 times higher than that in non-infected cells, and it inhibits viral replication in the following two ways: first, it competes with guanosine triphosphate to inhibit viral DNA polymerase; second, it binds to the DNA of viruses and host cells, resulting in termination of viral DNA synthesis. Although GCV can inhibit the DNA polymerase of KSHV, the water solubility of GCV makes it have low transmembrane ability against lipid-soluble cell plasma membranes, and it has poor specificity for the site of infection. Long-term high-dose treatment leads to many toxic side effects, such as thrombocytopenia, persistent bone marrow suppression, and severe liver and kidney damage. Therefore, the development of a GCV delivery system that increases the GCV concentration in target cells is a huge clinical challenge.

[0004] In recent years, the rapid development of nanotechnology and its interaction with multiple disciplines have provided new ideas for the treatment of cancer. Zeolite imidazolate framework-8 (ZIF-8) is a biocompatible porous material constructed by the coordination of zinc ions and 2-methylimidazole. The unique pH-responsive decomposition characteristics make ZIF-8 a promising drug delivery carrier, which can be used to effectively deliver GCV to the slightly acidic environment of the infection site. On the other hand, microneedle (MN) drug delivery has been widely used in the biomedical field. Microneedle drug delivery is a micro-invasive transdermal drug delivery method that combines the advantages of subcutaneous injection and skin patch. After the microneedle pierces the stratum corneum of the skin epidermis, a tiny channel is formed. The drug enters the skin along this channel, which increases its permeability and accumulation in specific parts. However, the soluble microneedles obtained by the traditional preparation method cannot be fully and effectively utilized after entering the skin. Because the skin has a certain elasticity, the microneedle body cannot be completely immersed in the skin. Only about half of the microneedle body can be completely dissolved in the skin, and the rest cannot be effectively utilized because it cannot be completely embedded below the stratum corneum, which limits the drug delivery efficiency and wastes part of the drug. Summary of the invention

[0005] In order to solve the above problems, the present invention provides a soluble microneedle patch for delivering ganciclovir, and a preparation method and application thereof. The needle tip of the needle body provided by the present invention is in a torch shape. The drug can be enriched at the position of the microneedle tip by a two-step centrifugal drying method. The contact area and drug loading amount are increased due to its torch shape, so that the drug can be quickly released from the microneedle, achieving the effect of local drug administration to treat Kaposi's sarcoma. On the other hand, since the needle tip is in a torch shape, the geometric shape of the torch microneedle includes a sharp skin penetrating tip, a wide skin interlocking body and a narrow base, and mechanical support is manufactured on the flexible hydrocolloid patch to improve the accuracy of skin penetration into irregular surfaces, further improve the utilization rate of the drug, and reduce the waste of the drug caused by the inability of the soluble microneedle body to fully enter the skin.

[0006] In order to achieve the above object, the present invention provides the following technical solutions:

[0007] The present invention provides a soluble microneedle patch for delivering ganciclovir, comprising a needle body and a backing layer, wherein the needle bodies are arranged in an array on the backing layer;

[0008] The needle body includes a matrix material and GCV@ZIF-8, wherein the GCV is ganciclovir;

[0009] A single needle is torch-shaped, with a torch height of 512 μm and a pyramid base height of 288 μm.

[0010] Preferably, the mass ratio of the matrix material to GCV@ZIF-8 is 5:4.

[0011] Preferably, the loading rate of ganciclovir on the GCV@ZIF-8 is 7-7.2%.

[0012] Preferably, the matrix material comprises hyaluronic acid, and the molecular weight of the hyaluronic acid is 40-100 kDa.

[0013] Preferably, the material of the backing layer is hyaluronic acid, and the molecular weight of the hyaluronic acid is 200-400 kDa.

[0014] Preferably, the needles are arranged on the backing layer in a 15×15 array.

[0015] The present invention also provides a method for preparing the soluble microneedle patch described in the above technical solution, comprising the following steps:

[0016] 1) Mixing the matrix material, GCV@ZIF-8 and water to obtain a needle material solution;

[0017] 2) placing the needle body material solution obtained in step 1) in a PDMS mold, centrifuging and drying to obtain a mold containing a needle body;

[0018] 3) placing the backing layer material solution in the mold containing the needle body in step 2), centrifuging and drying to obtain a soluble microneedle patch;

[0019] The mass percentage of the material in the backing layer solution is 5%.

[0020] Preferably, in step 1), the volume ratio of the mass of the matrix material, the mass of GCV@ZIF-8 and water is 50 mg:40 mg:1 mL.

[0021] Preferably, the centrifugal conditions in step 2) include: a rotation speed of 3000-3910 rpm and a time of 6 min; a drying temperature of 40° C. and a time of 120 min; and the centrifugation and drying are repeated twice;

[0022] The centrifugal conditions in step 3) include: a rotation speed of 2000-2500 rpm and a time of 6 minutes.

[0023] The present invention also provides the use of the soluble microneedle patch described in the above technical solution in the preparation of a Kaposi's sarcoma-associated herpes virus targeted diagnosis and treatment patch.

[0024] Beneficial effects of the present invention:

[0025] The ganciclovir soluble microneedle patch prepared by the present invention has good mechanical strength and sufficient mechanical properties to penetrate the skin, and the needle tip can dissolve quickly, thereby realizing the transdermal delivery of ganciclovir, improving the stability and transdermal absorption efficiency of the drug, reducing the toxic and side effects of the drug, and achieving the goal of accurately treating Kaposi's sarcoma with ganciclovir, with significant social and economic benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.

[0027] Figure 1 Characterization of the microneedle morphology: A1: morphology of the GCV@ZIF-8 torch microneedle under optical microscope; A2: fluorescence image of the rhodamine B torch microneedle; A3: SEM side view and top view of the torch microneedle;

[0028] Figure 2 To characterize the mechanical properties of microneedles - dynamometer test of the force-displacement curve of microneedles;

[0029] Figure 3 Characterization of the mechanical properties of microneedles - in vitro skin penetration test (rat skin): A1: Fluorescence images of different sections of the rat skin tested with rhodamine B-loaded ganciclovir soluble microneedles; A2: Top-down image of the ganciclovir microneedles after being attached to the rat skin;

[0030] Figure 4 Drug loading test of microneedles: release amount measured by in vitro transdermal experiment;

[0031] Figure 5 This is an experimental diagram of cell viability detection;

[0032] Figure 6 This is a graph showing changes in mouse body weight and tumor volume during treatment;

[0033] Figure 7 These are H&E staining images of the heart, liver, spleen, lungs, kidneys and tumors of mice after treatment. DETAILED DESCRIPTION

[0034] The present invention provides a soluble microneedle patch for delivering ganciclovir, comprising a needle body and a backing layer, wherein the needle bodies are arranged in an array on the backing layer; the needle body comprises a matrix material and GCV@ZIF-8, wherein the GCV is ganciclovir; a single needle body is torch-shaped, the torch height is 512 μm, and the height of the pyramid base is 288 μm.

[0035] In the present invention, the mass ratio of the matrix material and GCV@ZIF-8 is preferably 5:4. In the present invention, the loading rate of ganciclovir on the GCV@ZIF-8 is preferably 7 to 7.2%. The present invention does not specifically limit the preparation method of the GCV@ZIF-8, and a person skilled in the art can prepare it using a conventional preparation method. In the present invention, the matrix material preferably includes hyaluronic acid, and the molecular weight of the hyaluronic acid is preferably 40 to 100 kDa. In the present invention, the material of the backing layer is preferably hyaluronic acid, and the molecular weight of the hyaluronic acid is preferably 200 to 400 kDa. In the present invention, the needle body is preferably arranged on the backing layer in a 15×15 array.

[0036] The present invention also provides a method for preparing the soluble microneedle patch described in the above technical solution, comprising the following steps:

[0037] 1) Mixing the matrix material, GCV@ZIF-8 and water to obtain a needle material solution;

[0038] 2) placing the needle body material solution obtained in step 1) in a PDMS mold, centrifuging and drying to obtain a mold containing a needle body;

[0039] 3) placing the backing layer material solution in the mold containing the needle body in step 2), centrifuging and drying to obtain a soluble microneedle patch;

[0040] The mass percentage of the material in the backing layer solution is 5%.

[0041] The present invention mixes the matrix material, GCV@ZIF-8 and water to obtain a needle material solution. In the present invention, the mass of the matrix material, the mass of GCV@ZIF-8 and the volume ratio of water are preferably 50 mg:40 mg:1 mL. In the present invention, the water is preferably ultrapure water.

[0042] The present invention places the obtained needle body material solution in a PDMS mold, centrifuges and dries to obtain a mold containing a needle body. In the present invention, the centrifugal conditions preferably include: a rotation speed of 3000 to 3910 rpm and a time of 6 minutes. In the present invention, the drying temperature is preferably 40°C and the time is preferably 120 minutes. In the present invention, the centrifugation and drying are preferably repeated twice.

[0043] The present invention places a backing layer material solution in a mold containing a needle body, centrifuges and dries to obtain a soluble microneedle patch; the mass percentage of the material in the backing layer solution is 5%. In the present invention, the centrifugal conditions preferably include: a rotation speed of 2000-2500rpm and a time of 6min. In the present invention, the drying is preferably performed at room temperature. In the present invention, the backing layer solution includes material and ultrapure water.

[0044] The present invention also provides the use of the soluble microneedle patch described in the above technical solution in the preparation of a Kaposi's sarcoma-associated herpes virus targeted diagnosis and treatment patch.

[0045] In order to further illustrate the present invention, the present invention is described in detail below in conjunction with embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0046] The present invention is further described below in conjunction with specific examples, but the present invention is not limited to the following examples. The experimental methods in the following examples, unless otherwise specified, are conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels, and the room temperature described in the following examples refers to 25°C.

[0047] Example 1

[0048] Preparation of GCV@ZIF-8 loaded microneedles (i.e. soluble microneedle patches):

[0049] Matrix material of GCV@ZIF-8 loaded microneedles: Needle body material: GCV@ZIF-8 / HA mixed solution: 40 mg / mL GCV@ZIF-8 (GCV loading rate is 7.2%), 50 mg / mL HA (molecular weight is 40-100 kDa), the specific composition is as follows: 40 mg GCV@ZIF-8 + 1 mL ultrapure water + 50 mg HA; backing layer solution: 5% HA solution (HA: water = 1:20, w / w; HA molecular weight is 200-400 kDa).

[0050] The preparation method is as follows: place the above-mentioned needle material solution in a PDMS microneedle mold, centrifuge to remove bubbles, and then dry at 40°C for 120 minutes. Repeat twice to obtain a needle tip. The centrifugation conditions are: speed 3910 rpm, time 6 minutes; pour 650 μL of the backing layer solution in the PDMS microneedle mold, centrifuge again (speed 2500 rpm, time 6 minutes) to remove bubbles, and then dry at room temperature, and then demold to obtain the GCV@ZIF-8 soluble torch microneedle.

[0051] Figure 1 A1 is the morphology of the GCV@ZIF-8 soluble torch microneedle prepared in Example 1 characterized by an optical microscope; A3 is the SEM image of the GCV@ZIF-8 soluble torch microneedle.

[0052] Rhodamine B (a fluorescent dye used as a model drug for easy observation) with a mass percentage of 5% was added to the needle tip material in the above embodiment to obtain RhB@GCV@ZIF-8 soluble torch microneedle. Figure 1A2 in the middle is the morphology of the microneedles loaded with rhodamine B.

[0053] As can be seen from the figure, the microneedle is torch-shaped, with a height of 800μm, a torch height of 512μm, and a pyramid base height of 288μm. The morphology is uniform, which can ensure that the drug can be completely delivered into the body.

[0054] Example 2

[0055] Force-displacement curve of microneedle tested by dynamometer:

[0056] The specific test method is: the GCV@ZIF-8 soluble torch microneedle prepared in Example 1 is placed on a pressure tester for testing. The test results are as follows: Figure 2 As shown in the figure, a single needle can withstand a force of about 0.09N and can penetrate the skin. Therefore, from the force-displacement curve, it can be seen that the microneedle has sufficient mechanical properties to ensure that it can penetrate the skin without breaking.

[0057] Example 3

[0058] Characterization of mechanical properties of microneedles - in vitro skin penetration test (mouse back skin):

[0059] The GCV@ZIF-8 soluble torch microneedles prepared in Example 1 were subjected to an in vitro skin penetration test. The specific test method is as follows: In vivo penetration experiment in mice: the mice were anesthetized by passing 4% (w / v) isoflurane gas. After the mouse entered an anesthetized state, it was taken out and laid flat on the operating table. A small animal razor was used to trim the hair in the back area. An appropriate amount of depilatory cream was applied to the trimmed area and then wiped clean after 2 minutes to complete the removal of skin hair in the back area of ​​the mouse. Before attaching the soluble microneedle patch to the back skin of the mouse, the back skin was scrubbed clean with clean water and disinfected with an alcohol cotton pad. While the mouse was anesthetized, the microneedle was quickly pressed on the back skin of the mouse, kept for 5 minutes, and then removed. The pinholes in the back skin of the mouse were observed under an optical microscope. The above operation was repeated. After the rhodamine B-loaded patch was attached to the ex vivo skin of the mouse, the skin was fixed in neutral formalin, stained, and sliced. A fluorescence confocal microscope was used to observe the fluorescence images of the microneedles at different layers of the mouse skin and the cross-sectional images after staining. By Figure 3 From A1, we can see that there is fluorescence of dissolved microneedles at 220 μm below the skin, indicating that the microneedles have sufficient mechanical properties to penetrate the mouse skin. From A2, we can see that the microneedles can penetrate the subcutaneous part of the mouse's back, that is, the microneedles can pierce the skin and deliver the drug.

[0060] All mechanical property tests are performed to demonstrate that the prepared microneedles have sufficient mechanical properties to penetrate the skin for drug delivery.

[0061] Example 4

[0062] Microneedle release test:

[0063] The release amount of RhB@GCV@ZIF-8 microneedles prepared in the above embodiment was tested using a Franz diffusion cell. The specific test method is as follows: the simulated skin was placed between the supply chamber and the receiving chamber of the diffusion cell, 20 mL of PBS (pH = 7.4) was added to the receiving chamber, heated to 37 ° C, and the magnetic stirring speed was adjusted to 500 rpm. The Rhodamine B-loaded microneedle patch was placed on the skin in the supply chamber, and 600 μL of the receiving solution was taken out from the receiving chamber at 0h, 1h, 2h, 4h, 6h, 12h, 18h, 24h, 36h, 48h and 72h, and the fluorescence intensity was measured by a fluorescence detector.

[0064] The test results are as follows Figure 4 Shown by: Figure 4 The release curve shows that the soluble microneedles have been continuously releasing drugs and can reach a release effect of 90% in 24 hours, which can meet the needs of drug administration. After that, the release rate was measured until 120 hours, and it was still 90%, indicating that it had been completely released in 24 hours.

[0065] Example 5

[0066] Experiments on the effects on cell viability:

[0067] Model cells KSHV-positive KMM cells were selected, and PBS was used as the control group in the experiment. The MTT method was used to detect the effect of drugs on the viability of KMM cells. KMM cells were placed in a 96-well plate at a density of 5000 cells / well and incubated overnight in DMEM medium containing 10% FBS, 37°C, and 5% CO2. After the cells adhered to the wall, GCV and GCV@ZIF-8 were added to the culture medium. After continuing to culture for 24 hours, 10μL MTT solution was added to each well. After 4 hours, 100μL of triple solution was added to each well. After overnight, the absorbance at 490nm was measured using an enzyme reader. The effect of drugs on cell activity was calculated using the formula: Cell activity (%) = (absorbance value of the target group - absorbance value of the blank cell group) / (absorbance value of the control group - absorbance value of the blank cell group) × 100%. By Figure 5 It can be seen that GCV alone has little effect on cell viability and proliferation, while GCV encapsulated with ZIF-8 has a certain inhibitory effect on cell viability and proliferation, which can prove that the synthesized nanoparticles have certain medicinal effects.

[0068] Example 6

[0069] In vivo therapeutic effect experiment of the soluble microneedle prepared in Example 1: 25 female Balb / c mice of the same age were prepared, each mouse was injected with KMM cells to construct a model, and randomly divided into 5 groups, with five mice in each group, namely control group, blank microneedle group, microneedle group loaded with ZIF-8, drug injection group and microneedle (soluble microneedle patch prepared in Example 1) treatment group. The control group did not receive any treatment, the injection group and the microneedle group were treated once every four days, the drug injection group adopted the method of peritumoral injection, and each mouse was injected with 100μL GCV@ZIF-8 nanodrug; the mice in the microneedle treatment group were anesthetized with isoflurane and the microneedles were attached to the tumor for treatment, and the weight and tumor volume of the mice were recorded every four days. Figure 6 It can be seen that the weight of mice increased during the treatment, indicating that the treatment process was very toxic to the mice; compared with the control group, the tumor volume of the treatment group was significantly reduced, indicating that microneedling has a significant therapeutic effect on tumors.

[0070] Example 7

[0071] H&E staining. After the in vivo experiment of mice in Example 6, the heart, liver, spleen, lung, kidney and tumor of the mice were taken and fixed for H&E staining analysis. Figure 7 It can be seen that the cytoplasm of the cancer cells in the control group and the blank microneedle group is richer, the cell nuclei overlap with each other, and the heteromorphism is obvious, which is quite different from the experimental group. However, there is no obvious difference in the heart, liver, spleen, lung, and kidney of the mice, and they are arranged evenly, indicating that there is no obvious toxicity to mice.

[0072] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A soluble microneedle patch for delivering ganciclovir, characterized in that: It comprises needle bodies and a backing layer, wherein the needle bodies are arranged in an array on the backing layer; The needle body includes a matrix material and GCV@ZIF-8, wherein the GCV is ganciclovir; A single needle is torch-shaped, with a torch height of 512 μm and a pyramid base height of 288 μm.

2. The soluble microneedle patch according to claim 1, characterized in that: The mass ratio of the matrix material to GCV@ZIF-8 is 5:

4.

3. The soluble microneedle patch according to claim 1 or 2, characterized in that: The loading rate of ganciclovir on the GCV@ZIF-8 is 7-7.2%.

4. The soluble microneedle patch according to claim 1 or 2, characterized in that: The matrix material comprises hyaluronic acid, and the molecular weight of the hyaluronic acid is 40-100 kDa.

5. The soluble microneedle patch according to claim 1, characterized in that: The material of the backing layer is hyaluronic acid, and the molecular weight of the hyaluronic acid is 200-400 kDa.

6. The soluble microneedle patch according to claim 1, characterized in that: The needles are arranged on the backing layer in a 15×15 array.

7. A method for preparing the soluble microneedle patch according to any one of claims 1 to 6, characterized in that: The following steps are involved: 1) Mixing the matrix material, GCV@ZIF-8 and water to obtain a needle material solution; 2) placing the needle body material solution obtained in step 1) in a PDMS mold, centrifuging and drying to obtain a mold containing a needle body; 3) placing the backing layer material solution in the mold containing the needle body in step 2), centrifuging and drying to obtain a soluble microneedle patch; The mass percentage of the material in the backing layer solution is 5%.

8. The preparation method according to claim 7, characterized in that: In the step 1), the mass of the matrix material, the mass of GCV@ZIF-8 and the volume ratio of water are 50 mg:40 mg:1 mL.

9. The preparation method according to claim 7, characterized in that: The centrifugal conditions in step 2) include: a rotation speed of 3000-3910 rpm and a time of 6 min; a drying temperature of 40° C. and a time of 120 min; and the centrifugation and drying are repeated twice; The centrifugal conditions in step 3) include: a rotation speed of 2000-2500 rpm and a time of 6 minutes.

10. Use of the soluble microneedle patch according to any one of claims 1 to 6 in preparing a Kaposi's sarcoma-associated herpes virus targeted diagnosis and treatment patch.